Flovent hfa and Jakafi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Flovent hfa (fluticasone propionate) and Jakafi (ruxolitinib phosphate). Common drug interactions include heart rate increased among females and abdominal distension among males.

The phase IV clinical study analyzes what interactions people have when they take Flovent hfa and Jakafi. It is created by eHealthMe based on reports of 49 people who take the same drugs from the FDA, and is updated regularly.

What is Flovent hfa?

Flovent hfa has active ingredients of fluticasone propionate. It is often used in asthma. eHealthMe is studying from 7,457 Flovent hfa users. Check the latest studies of Flovent hfa.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

49 people who take Flovent hfa and Jakafi together, and have interactions are studied.

Flovent hfa and Jakafi drug interactions.

What are the common drug interactions of Flovent Hfa and Jakafi, by gender? *:

female:

Heart rate increased
Back pain
Cardiac murmur (an heart sound in valve abnormality)
Dizziness
International normalised ratio decreased
Nasopharyngitis (inflammation of the nasopharynx)
Oedema (fluid collection in tissue)
Pain in extremity
Prothrombin time ratio increased
Weight increased

male:

Abdominal distension
Anaemia (lack of blood)
Fatigue (feeling of tiredness)
Globulins increased
Glomerular filtration rate decreased
Haematocrit decreased
Haemoglobin decreased
Hepatomegaly (abnormal enlargement of the liver)
Leukocytosis (increased white blood cells)
Mean cell volume decreased (less of the average red blood cell volume)

What are the common drug interactions of Flovent Hfa and Jakafi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Death

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Blood pressure increased
Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
Cough
Cytomegalovirus viraemia (cytomegalo virus in blood stream)
Dysplasia (enlargement of an organ or tissue)
Heart rate increased
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection)
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
Immunosuppression
Infection susceptibility increased

60+:

Back pain
Abdominal distension
Fatigue (feeling of tiredness)
Globulins increased
Glomerular filtration rate decreased
Haematocrit decreased
Haemoglobin decreased
Hepatomegaly (abnormal enlargement of the liver)
Leukocytosis (increased white blood cells)
Mean cell volume decreased (less of the average red blood cell volume)

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 10 people, 20.41%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 5 people, 10.20%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 4 people, 8.16%
Weight Loss: 3 people, 6.12%
Stress And Anxiety: 3 people, 6.12%
Neoplasm Malignant (cancer tumour): 3 people, 6.12%
Mouth Ulcers: 3 people, 6.12%
Behcet's Syndrome (involves inflammation of the blood vessels): 3 people, 6.12%

* Approximation only. Some reports may have incomplete information.

Do you take Flovent hfa and Jakafi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously